The firm is investing in commercial resources and research and development to capitalize on continued expansion in the global tuberculosis market, according to its CEO.
The firm said that total revenue was lower than expected due to the timing of orders in its flow cytometry operations in the third quarter.
The Temple City, California-based NGS genetic testing firm more than doubled its number of billable tests compared to the prior-year period.
The firm said it is tackling challenges in its Diagnostics business, which had 2 percent growth year over year on a comparable basis in its fiscal fourth quarter.
The company reported $33.8 million in total revenues for the quarter and said testing services revenues rose 68 percent year over year.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.
Clinical services revenues rose 56 percent to $92.6 million while pharma services grew 26 percent to $12.1 million.
The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.